Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are evaluating the effects of BAY 3670549 in adults with atrial fibrillation who require electrical cardioversion. The study aims to understand how well BAY 3670549 works to restore normal heart rhythm, how safe and tolerable it is, and how the body processes this medicine. Participants will receive either BAY 3670549 or a placebo to compare outcomes. Each participant will receive a single intravenous infusion of BAY 3670549 or a placebo. After this, researchers will observe whether the heart rhythm returns to normal without needing electrical cardioversion. If the heart rhythm does not revert, electrical cardioversion can still be performed as planned. The study measures how many participants convert to normal rhythm and how quickly, as well as any medical issues after treatment and the medicines pharmacokinetics. Participants will be involved for up to two months. During this time, their heart rhythm will be closely monitored, and safety assessments for any adverse events will be conducted up to 48 hours after treatment. Blood samples will be taken to measure the medicine concentration. The primary outcome is the number of participants whose heart rhythm converts to normal within 3 hours without additional treatment, providing important data on the treatments impact on atrial fibrillation.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of different doses of the drug AP31969 in reducing the burden of Atrial Fibrillation AF. The trial is a randomized Phase 2 study comparing several doses of AP31969 against a placebo in adults diagnosed with paroxysmal or persistent AF. Participants are carefully selected based on their AF history and burden, and the study monitors heart rhythm using implanted devices. Participants are assigned randomly to one of five groups receiving oral tablets twice daily for 12 weeks AP31969 at doses of 100 mg, 200 mg, 350 mg, or 500 mg added later, or a placebo without active properties. The study consists of three main periods screening up to 4 weeks, treatment 12 weeks, and a follow-up period of 30 days, totaling about 20 weeks. During the study, participants receive an implantable loop recorder to continuously monitor heart rhythm. Throughout the trial, participants undergo several assessments including blood and urine tests, electrocardiograms, and continuous rhythm monitoring via the loop recorder. The main outcome measured is the AF burden from weeks 2 to 12, with additional measures including the number of AF episodes, quality of life changes, and ventricular tachycardia episodes. Safety and adherence are closely monitored, and the follow-up period helps assess sustained effects and participant well-being after treatment ends.
Actively Recruiting
Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.
Actively Recruiting
This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
Researchers are collecting and analyzing real-world data from multiple centers in Italy and Poland on the use of the PERCUTEK Tycheseal stent-graft system for repairing abdominal aortic aneurysms AAA. The study aims to evaluate the technical success, safety, and mid-term outcomes of this device in actual clinical practice. It focuses on patients with suitable anatomy undergoing this procedure, to provide evidence on the devices performance and related complications over time. This is an observational, physician-initiated registry enrolling 120 to 200 patients over about 18 months. Participants receive the PERCUTEK Tycheseal tri-modular endograft system, which includes a main body and two iliac limbs designed to fit a range of aortic anatomies. The device features a low-profile delivery system and radiopaque markers to aid placement. Data on the procedure and outcomes are collected without experimental treatments or randomization. Participants are followed for up to 24 months after device implantation with assessments at baseline, discharge, 1 month, 12 months, and 24 months. Study measures include technical success defined by proper device positioning and no immediate serious leaks, aneurysm size changes, endoleak presence, device migration or occlusion, and major adverse events. Data are collected using standardized forms, and safety outcomes are monitored throughout the study period to understand the devices mid-term clinical performance.
1-10 of 15
1